Recent Press Releases

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

Princeton, NJ – September 19, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs...

Inovio Pharmaceuticals Ebola Vaccine Moving into Human Trial with GeneOne Life Science

PLYMOUTH MEETING, Pa., Sept. 24, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a collaboration...

Novavax' H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2 Clinical Data

Novavax' H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2 Clinical Data September 23, 2014: 08:30 AM ET Vaccine and adjuvant were well-tolerated,...

Pfizer Foundation Provides $2 Million In Grants To Support 'Last-Mile' Vaccine Coverage In Africa

Pfizer Foundation Provides $2 Million In Grants To Support 'Last-Mile' Vaccine Coverage In Africa Efforts in support of the United Nations Millennium Development Goal (MDG) 4 to reduce under-5...

Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery

Genocea Announces $1.2 Million Grant for Malaria Vaccine Discovery CAMBRIDGE, Mass., Sep 23, 2014 (BUSINESS WIRE) -- Genocea Biosciences, Inc. GNCA, -4.02% a clinical-stage biopharmaceutical company...

Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer

MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an...

Japanese Global Health Fund awards $33.5 million to develop vaccines, drugs for neglected diseases

Seven new grant investments for $15.3 million to tackle malaria, chagas disease and dengue, which is dramatically on the rise TOKYO, JAPAN (September 16, 2014)—The Global Health Innovative...

Takeda Announces Reorganization to Propel Continued Growth

Osaka, Japan, September, 16th, 2014 – Takeda Pharmaceutical Company Limited ("Takeda") today announced plans to redesign its global organizational structure to realize its goal of...

Protein Sciences and Diamyd Medical Deepen Commitment to Develop New Treatment for Diabetes

MERIDEN, Conn. and STOCKHOLM, Sept. 16, 2014 /PRNewswire/ -- Protein Sciences Corporation and Diamyd Medical AB announced today that Protein Sciences has broadened its commitment to diabetes and...

Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

DARMSTADT, Germany, Sept. 12, 2014 /CNW/ - Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its...

FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease

HEADLINE2Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination SWIFTWATER, Pa., Sept. 8, 2014 /PRNewswire-USNewswire/ -- Sanofi...

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients

New breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is...

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology

New patent includes composition of matter claims PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (otcqb:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company...

PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine

ANNAPOLIS, Md., Sept. 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (nyse mkt:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that...

FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine

AMES, IA -- (Marketwired) -- 09/04/14 -- NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the United States Food and Drug Administration (FDA) has given permission for the Company to...

Johnson & Johnson Responds to Ebola Crisis with Commitment to Accelerate Vaccine Program in Collaboration with the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

NEW BRUNSWICK, NJ, September 4, 2014 – Johnson & Johnson today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly...

New Analysis of Old HIV Vaccines Finds Potentially Protective Immune Response

Newswise — DURHAM, N.C. – Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging...

Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer

REDWOOD CITY, Calif., Sep 03, 2014 (BUSINESS WIRE) -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice...

SANOFI PASTEUR'S DENGUE VACCINE CANDIDATE SUCCESSFULLY COMPLETES FINAL LANDMARK PHASE III CLINICAL EFFICACY STUDY IN LATIN AMERICA

- Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes - - Additional...

Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency

First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission...